Genworth Financial (GNW) Earnings Date & Reports

Key Takeaways

• Genworth Financial is scheduled to report second-quarter 2026 results after the market closes on August 5, 2026, with a conference call to follow on August 6.
• Analyst consensus estimates for adjusted operating earnings per share (EPS) center around $0.28, roughly in line with the first quarter's result.
• Enact, Genworth's mortgage insurance subsidiary and primary cash-flow engine, remains the most closely watched segment heading into the report.
• The AXA litigation appeal hearing concluded July 21–23, and any commentary from management on its outcome could move the stock.
• Investors will scrutinize CareScout's revenue trajectory and the Closed Block's quarterly loss trends for signs of progress or deterioration.

Earnings Context and Why It Matters

Genworth Financial's upcoming second-quarter report lands at a pivotal moment for the Richmond, Virginia-based insurer. The company has been methodically reshaping its narrative around two core themes: harvesting steady cash flows from Enact, its approximately 81%-owned mortgage insurance subsidiary, and planting long-term growth seeds through CareScout, an aging-care services platform targeting America's 70 million baby boomers. Meanwhile, the legacy Closed Block of long-term care (LTC), life insurance, and annuity products continues to require active management. With the stock trading near its 52-week high of $10.20 and a recent analyst upgrade lifting sentiment, this earnings release will test whether Genworth's multi-pronged strategy can sustain investor confidence.

Earnings Expectations

Wall Street is looking for Genworth to deliver adjusted operating earnings per share (excluding the Closed Block) of approximately $0.28 for the second quarter, according to consensus data tracked by several financial platforms. That would match the first quarter's result, when the company posted adjusted operating income of $109 million, or $0.28 per diluted share. On a GAAP (Generally Accepted Accounting Principles) basis, analysts project net income per share closer to $0.07. Revenue estimates are less uniform across the Street, though the first quarter's top-line figure of approximately $1.78 billion in total revenues provides a baseline reference point.

Key metrics investors will be watching include Enact's primary new insurance written (NIW), its PMIERs (Private Mortgage Insurer Eligibility Requirements) sufficiency ratio — which stood at a robust 162% in the first quarter — and its loss ratio. For CareScout, the market will focus on quarterly match volume and progress toward the full-year target of approximately 7,500 matches and $25 million in service revenue. The Closed Block's adjusted operating loss and any updates to the company's full-year expectation of roughly $300 million in pre-tax actual-to-expected (A/E) losses will also be under the microscope.

AI Screener

For investors seeking to identify opportunities beyond individual earnings reports, Tickeron's AI Screener offers a powerful AI-driven stock and ETF discovery tool designed to streamline market research. The platform allows users to filter thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, and performance metrics. By surfacing trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, the AI Screener helps both traders and active investors stay ahead of market movements. Explore the AI Screener to see how data-driven filtering can sharpen your market perspective.

Market Reaction and Investor Sentiment

Genworth shares closed at $9.90 on July 27, 2026, up roughly 10% year-to-date and hovering within striking distance of the stock's 52-week high of $10.20. The stock has generally trended higher through July, buoyed by constructive analyst commentary. Keefe, Bruyette & Woods recently raised its price target to $12.00, while DOWLING & PARTN sharply lifted its full-year 2026 EPS estimate to $1.10 — well above the broader consensus of approximately $0.44. Sentiment is cautiously optimistic but not euphoric; Wall Street Zen upgraded the stock from "sell" to "hold" earlier in July, and the overall analyst consensus sits at "Moderate Buy." Key risks heading into the print include potential disappointment in Enact's quarterly performance, any negative deviation in Closed Block loss trends, and ongoing macroeconomic uncertainty around interest rates and housing market conditions.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, several forward-looking catalysts deserve investor attention. First, the AXA litigation remains a significant wildcard. The appeal hearing took place from July 21 through July 23, and management may offer preliminary feedback during the earnings call. A favorable outcome could eventually unlock approximately $750 million in recoveries, which Genworth has stated would be deployed toward CareScout investment, share repurchases, and debt reduction — though none of this is currently baked into capital allocation plans.

Second, Enact's capital return capacity will be front and center. In the first quarter, Genworth received $99 million in capital returns from Enact, and management has guided to approximately $405 million for the full year. Any revision to that outlook — up or down — would directly affect Genworth's ability to sustain share buybacks, which totaled $66 million in the first quarter alone.

Third, CareScout's scaling trajectory matters for the long-term growth story. The company expects to have more than 1,000 home care locations and approximately 2,000 senior living communities in its CareScout Quality Network by year-end. The planned launch of the CareAssurance worksite product later this year adds another potential growth layer, though it remains early-stage.

Finally, the Closed Block's Multi-Year Rate Action Plan (MYRAP) continues to progress, with approximately $34.5 billion in estimated net present value achieved since 2012 through premium increases and benefit reductions. With the company targeting roughly $1 billion in additional economic value from 2026 premium approvals and benefit reductions, any update to pacing or regulatory developments will be noteworthy for investors focused on legacy liability management.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations